Trials / Recruiting
RecruitingNCT06424964
Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Belgian Research on AIDS and HIV Consortium · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes. Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV Secondary outcomes • Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis
Conditions
Timeline
- Start date
- 2025-01-13
- Primary completion
- 2025-05-01
- Completion
- 2025-07-01
- First posted
- 2024-05-22
- Last updated
- 2025-02-05
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06424964. Inclusion in this directory is not an endorsement.